MHC class II ligation induces CD58 (LFA-3)-mediated adhesion in human T cells.
MHC class II positive T cells found in areas of inflammation are believed to play an important pathogenetic role in autoimmunity. In experimental models , class II molecules have been shown to regulate adhesion between human T cells. It is, however, not known in detail how class II molecules are functionally linked to adhesion molecules. Some data suggest that beta2 integrin (CD11a/CD18) molecules play a role in class-II-induced homotypic adhesion in B cells, monocytes, and virus-transformed or neoplastic cell lines. We have previously obtained evidence that adhesion molecules other than beta2 integrins might play a role in class-II-mediated adhesion in T cells. To study further class-II-mediated adhesion in T cells, we have taken advantage of (allo)antigen-specific beta2-integrin-negative, CD4-positive T cell lines obtained from a leukocyte adhesion deficiency patient. We show that class II ligation induces homotypic adhesion in both beta2-integrin-positive and negative, CD4-positive T cell lines. Anti-CD18 monoclonal antibody (mAb) weakly inhibited the adhesion response in beta2-integrin-positive T cells and had no effect on beta2-integrin-negative T cells. In contrast, an anti-CD58 (LFA-3) mAb almost completely inhibited the adhesion response in beta2-integrin-negative T cells. Antibodies against the CD58 ligand, CD2, partly inhibited the adhesion response in beta2-integrin-negative T cells whereas antibodies against other adhesion molecules did not. The adhesion response in beta2-integrin-positive T cells was partly inhibited by antibodies against CD58 and CD2. Taken together, these data provide the first evidence that CD58 molecules are involved in class-II-induced homotypic adhesion between T cells.
Institute of Microbiology and Immunology, University of Copenhagen, Copenhagen, Denmark.
M
M
Nielsen
J
J
Gerwien
C
C
Geisler
C
C
Röpke
A
A
Svejgaard
N
N
Odum
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D016227:Benzoquinones; D018821:CD18 Antigens / Q000378:metabolism; D018801:CD2 Antigens / Q000378:metabolism; D018968:CD58 Antigens / Q000378:metabolism*; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology*; D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D006801:Humans; D047029:Lactams, Macrocyclic; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011809:Quinones / Q000494:pharmacology; D017828:Rifabutin / Q000031:analogs & derivatives; D013601:T-Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016227:Benzoquinones; D018821:CD18 Antigens; D018801:CD2 Antigens; D018968:CD58 Antigens; D004791:Enzyme Inhibitors; D000949:Histocompatibility Antigens Class II; D047029:Lactams, Macrocyclic; D011809:Quinones; D017828:Rifabutin; C020754:herbimycin; D011505:Protein-Tyrosine Kinases